Cargando…
PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的治疗进展
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. The results of clinical trials revea...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972971/ https://www.ncbi.nlm.nih.gov/pubmed/28228226 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.02.09 |